Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist

Joseph P Lyssikatos

Chief Scientific Officer at Enliven Therapeutics, Inc. (ELVN)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $4.8M

Reported trades

Filed Stock Type Shares Price Value Since
Feb 10SEC ELVNEnliven Therapeutics, Inc. Sell Plan 5,000740,188 held (−1%) $29.04 $145K +41.1%
Jan 22SEC ELVNEnliven Therapeutics, Inc. Sell Plan 5,491759,697 held (−1%) $26.37 $145K +55.4%
Jan 22SEC ELVNEnliven Therapeutics, Inc. Sell Plan 14,509745,188 held (−2%) $26.90 $390K +52.3%
Jan 12SEC ELVNEnliven Therapeutics, Inc. Sell Plan 7,500890,188 held (−1%) $20.13 $151K +103.6%
Jan 12SEC ELVNEnliven Therapeutics, Inc. Sell Plan 33,802856,386 held (−4%) $24.92 $842K +64.4%
Jan 12SEC ELVNEnliven Therapeutics, Inc. Sell Plan 41,198815,188 held (−5%) $24.90 $1.0M +64.6%
Jan 12SEC ELVNEnliven Therapeutics, Inc. Sell Plan 50,000765,188 held (−6%) $29.13 $1.5M +40.7%
Dec 23SEC ELVNEnliven Therapeutics, Inc. Sell Plan 5,000897,688 held (−1%) $16.84 $84K +143.3%
Nov 21SEC ELVNEnliven Therapeutics, Inc. Sell Plan 12,008903,180 held (−1%) $22.30 $268K +83.8%
Nov 21SEC ELVNEnliven Therapeutics, Inc. Sell Plan 492902,688 held (−0%) $23.09 $11K +77.5%
Oct 22SEC ELVNEnliven Therapeutics, Inc. Sell Plan 12,500915,188 held (−1%) $22.08 $276K +85.6%
  • Sell

    Chief Scientific Officer Joseph P Lyssikatos sold $145K of ELVN at $29.04 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Chief Scientific Officer Joseph P Lyssikatos sold $145K of ELVN at $26.37 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Chief Scientific Officer Joseph P Lyssikatos sold $390K of ELVN at $26.90 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Chief Scientific Officer Joseph P Lyssikatos sold $151K of ELVN at $20.13 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Chief Scientific Officer Joseph P Lyssikatos sold $842K of ELVN at $24.92 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Chief Scientific Officer Joseph P Lyssikatos sold $1.0M of ELVN at $24.90 — pre-scheduled 10b5-1 plan sale.